View Past PerformancePYC Therapeutics バランスシートの健全性財務の健全性 基準チェック /66PYC Therapeuticsの総株主資本はA$147.3M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$159.1MとA$11.8Mです。主要情報0%負債資本比率AU$0負債インタレスト・カバレッジ・レシオn/a現金AU$120.69mエクイティAU$147.33m負債合計AU$11.80m総資産AU$159.13m財務の健全性に関する最新情報お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.すべての更新を表示Recent updatesお知らせ • Jun 15PYC Therapeutics Announces Company Secretary Changes, Effective June 15, 2026PYC Therapeutics Limited advised that Mr. Stephen Ledger and Mr. Jonathan Riley had been appointed as joint Company Secretaries of the Company effective June 15, 2026. Mr. Ledger is an experienced Company Secretary who holds a Bachelor of Commerce from the University of Western Australia. He currently serves as a Non-Executive Director for Bertling Logistics Australia and ArcelorMittal Projects Australia, and is Founder and Executive Director of Ledger Financial Group. Mr. Riley is an experienced legal counsel who holds a Bachelor of Laws and Bachelor of Science (Pharmacology) from the University of Western Australia. Prior to joining PYC, Mr. Riley held a senior legal role at CSL Limited in Melbourne. For the purposes of ASX Listing Rule 12.6, Mr. Ledger will be responsible for communications with ASX in relation to Listing Rule matters. Mr. Daniel Coletta has resigned as Company Secretary effective June 15, 2026.お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listingお知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listingお知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listingお知らせ • Oct 18PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australiaお知らせ • Sep 22Pyc Therapeutics Limited Announces Board ChangesPYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director.お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Apr 10PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003.お知らせ • Feb 18PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 116,651,930 Price\Range: AUD 1.25 Transaction Features: Rights Offering財務状況分析短期負債: PYCX.Fの 短期資産 ( A$153.7M ) が 短期負債 ( A$11.0M ) を超えています。長期負債: PYCX.Fの短期資産 ( A$153.7M ) が 長期負債 ( A$791.5K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: PYCX.Fは負債がありません。負債の削減: PYCX.F過去 5 年間負債を抱えていません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: PYCX.Fは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: PYCX.Fは、フリー キャッシュ フローが毎年34.7 % の歴史的率で減少し続ける場合、 1.7年間十分なキャッシュ ランウェイを有しています。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 21:33終値2026/06/29 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PYC Therapeutics Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Melissa BensonBarrenjoey Markets Pty LimitedThomas WakimBell PotterDavid MartinBloom Burton & Co.4 その他のアナリストを表示
お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Jun 15PYC Therapeutics Announces Company Secretary Changes, Effective June 15, 2026PYC Therapeutics Limited advised that Mr. Stephen Ledger and Mr. Jonathan Riley had been appointed as joint Company Secretaries of the Company effective June 15, 2026. Mr. Ledger is an experienced Company Secretary who holds a Bachelor of Commerce from the University of Western Australia. He currently serves as a Non-Executive Director for Bertling Logistics Australia and ArcelorMittal Projects Australia, and is Founder and Executive Director of Ledger Financial Group. Mr. Riley is an experienced legal counsel who holds a Bachelor of Laws and Bachelor of Science (Pharmacology) from the University of Western Australia. Prior to joining PYC, Mr. Riley held a senior legal role at CSL Limited in Melbourne. For the purposes of ASX Listing Rule 12.6, Mr. Ledger will be responsible for communications with ASX in relation to Listing Rule matters. Mr. Daniel Coletta has resigned as Company Secretary effective June 15, 2026.
お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listing
お知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 18PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australia
お知らせ • Sep 22Pyc Therapeutics Limited Announces Board ChangesPYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director.
お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Apr 10PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003.
お知らせ • Feb 18PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 116,651,930 Price\Range: AUD 1.25 Transaction Features: Rights Offering